{
    "id": 4441,
    "fullName": "MTOR F2108L",
    "impact": "missense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "MTOR F2108L lies within the FKBP1A/rapamycin complex-interacting region of the Mtor protein (UniProt.org). F2108L results in the loss of mTOR's ability to bind rapamycin analogs (PMID: 25295501).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2388,
                    "pubMedId": 25295501,
                    "title": "Response and acquired resistance to everolimus in anaplastic thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25295501"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2475,
        "geneSymbol": "MTOR",
        "terms": [
            "MTOR",
            "FRAP",
            "FRAP1",
            "FRAP2",
            "RAFT1",
            "RAPT1",
            "SKS"
        ]
    },
    "variant": "F2108L",
    "createDate": "04/03/2015",
    "updateDate": "02/28/2020",
    "referenceTranscriptCoordinates": {
        "id": 145211,
        "transcript": "NM_004958",
        "gDna": "chr1:g.11127039A>G",
        "cDna": "c.6322T>C",
        "protein": "p.F2108L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1902,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a thyroid cancer patient became resistant to Afinitor (everolimus) after 18-months and was found to have acquired the mutation, mTOR F2108L (PMID: 25295501; NCT00936858).",
            "molecularProfile": {
                "id": 4237,
                "profileName": "MTOR F2108L"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 2388,
                    "pubMedId": 25295501,
                    "title": "Response and acquired resistance to everolimus in anaplastic thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25295501"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3369,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells expressing MTOR F2108L were resistant to Rapamune (sirolimus) mediated growth inhibition in culture (PMID: 25295501).",
            "molecularProfile": {
                "id": 4237,
                "profileName": "MTOR F2108L"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2388,
                    "pubMedId": 25295501,
                    "title": "Response and acquired resistance to everolimus in anaplastic thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25295501"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3371,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Torin 1 inhibited growth of transformed human cells expressing MTOR F2108L in culture (PMID: 25295501).",
            "molecularProfile": {
                "id": 4237,
                "profileName": "MTOR F2108L"
            },
            "therapy": {
                "id": 2247,
                "therapyName": "Torin 1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2388,
                    "pubMedId": 25295501,
                    "title": "Response and acquired resistance to everolimus in anaplastic thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25295501"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7493,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing both MTOR F2108L and MTOR M2327I demonstrated sensitivity to treatment with RapaLink-1 in culture, resulting in inhibition of Mtor and downstream signaling (PMID: 27279227).",
            "molecularProfile": {
                "id": 25591,
                "profileName": "MTOR F2108L MTOR M2327I"
            },
            "therapy": {
                "id": 4493,
                "therapyName": "RapaLink-1",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7494,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing both MTOR F2108L and MTOR M2327I demonstrated resistance to treatment with Rapamune (sirolimus) in culture (PMID: 27279227).",
            "molecularProfile": {
                "id": 25591,
                "profileName": "MTOR F2108L MTOR M2327I"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7495,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing both MTOR F2108L and MTOR M2327I demonstrated resistance to treatment with Sapanisertib (MLN0128) in culture (PMID: 27279227).",
            "molecularProfile": {
                "id": 25591,
                "profileName": "MTOR F2108L MTOR M2327I"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7496,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer cell line expressing both MTOR F2108L and MTOR M2327I demonstrated resistance to the combination treatment of Rapamune (sirolimus) and Sapanisertib (MLN0128) in culture (PMID: 27279227).",
            "molecularProfile": {
                "id": 25591,
                "profileName": "MTOR F2108L MTOR M2327I"
            },
            "therapy": {
                "id": 4497,
                "therapyName": "Sapanisertib + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6367,
                    "pubMedId": 27279227,
                    "title": "Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27279227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 4237,
            "profileName": "MTOR F2108L",
            "profileTreatmentApproaches": [
                {
                    "id": 2854,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "MTOR F2108L"
                },
                {
                    "id": 2853,
                    "name": "mTOR Inhibitor",
                    "profileName": "MTOR F2108L"
                }
            ]
        },
        {
            "id": 25591,
            "profileName": "MTOR F2108L MTOR M2327I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145211,
            "transcript": "NM_004958",
            "gDna": "chr1:g.11127039A>G",
            "cDna": "c.6322T>C",
            "protein": "p.F2108L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145212,
            "transcript": "XM_005263438",
            "gDna": "chr1:g.11127039A>G",
            "cDna": "c.6322T>C",
            "protein": "p.F2108L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}